Search in the Abstract Database

Search Abstracts 2013

* = Presenting author

P446. Long term outcome of azathioprine therapy in 353 consecutive IBD patients

H. Johnson1, K. Smith2, N. Jarrett1, S. McLaughlin1, S. Weaver1, 1Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom, 2Yeovil District Hospital, Department of Gastroenterology, Yeovil, United Kingdom


Thiopurines are the mainstay of therapy in Inflammatory Bowel Disease (IBD). However they have a wide range of side effects which can limit their use. To assess how effective AZA was in IBD, and what its limitations were, the outcome of 353 consecutive IBD patients started on AZA with at least one year follow up was assessed.


Since 2005 all patients started on AZA for IBD have been recorded and monitored. These data were then used to assess the outcome of patients where there had been at least one year of follow up. Outcomes recorded were whether AZA was still being taken or not. If still being taken information about the disease activity was recorded. If AZA therapy had been discontinued then the reason for this was recorded and subsequent therapeutic interventions noted.


353 patients had started AZA and had at least one year of follow up. TPMT status was checked in all patients. Dosing was as follows: low TPMT; AZA 50 mg and increased as tolerated. Normal TPMT; 2–2.5 mg/kg.

Of the 353 patients, 204 had Crohn's Disease (CD), 141 had Ulcerative Colitis and 8 had IBD-unclassified. The male:female ratio was 184:169 (52.1% male). Age range was 16–86 years (mean; 46). 322/353 (91%) remain under follow up.

127 (36%) of patients had stopped taking AZA at one year. After six years 152 (43.1%) remained on AZA, 182 (51.6%) had stopped and in 19 (5%) the outcome was unknown. Nausea and myalgia were the main reasons for stopping AZA. 40 (11.3%) patients developed hepatitis (ALT rise >2×ULN), 6 (1.7%) developed myelosuppression and 7 (2%) developed pancreatitis (consistent clinical presentation and raised amylase). Of the 182 patients who stopped AZA, 67 (37.8%) had an escalation of therapy – 20 started methotrexate, 18 started biologics and 29 underwent surgery.

Of the 152 who continued AZA, 138 (90.8%) were in a clinical remission based on clinical assessment supported by normal C-reactive protein in 126 (91.3%), Harvey Bradshaw Index in those with CD 55 (40%) patients and endoscopic findings in 22 (15.9%). 112 (73.6%) patients had blood monitoring (FBC and LFTs) at least quarterly and 147 (96.7%) at least bi-annually.


A significant number of patients stop AZA due to side effects. This study highlights these so that patients can be accurately informed. It also shows that AZA when tolerated is a very effective maintenance medication. Alternative prescribing strategies, such as low dose AZA with allopurinol, may limit side effects and maintain efficacy.